Table 2 Histological characteristics of patients with or without central fibrous area in the glomerular vascular pole
Total (n = 101) | CFA (+) (n = 56) | CFA (−) (n = 45) | p value | |
|---|---|---|---|---|
Number of CFA, n, median (IQR) | 1 (0–3) | 2 (2–3.25) | 0 (0–0) | ― |
Number of glomeruli, n, median (IQR) | 22 (16–31) | 21 (15–31.75) | 22 (18–30) | 0.49 |
Global glomerulosclerosis, n, median (IQR) | 1 (0–3) | 1 (0–3.25) | 1 (0–2) | 0.58 |
CFA-positive ratio, %, median (IQR) | 5.3 (0–12.5) | 11.1 (8.3–17.9) | 0 (0–0) | ― |
Segmental glomerulosclerosis, n, median (IQR) | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.97 |
Glomerular tuft size (μm2), median (IQR) | 13,282 (10,808–16,797) | 12,957 (10,893–16,834) | 13,775 (10,786–16,632) | 0.67 |
Elastofibrosis in the interlobular artery, n (%) | 61 (63.5) | 40 (75.5) | 21 (48.8) | 0.0022 |
Mild, n (%) | 19 (19.8) | 10 (18.9) | 9 (20.9) | |
Moderate, n (%) | 12 (12.5) | 9 (17.0) | 3 (7.0) | |
Severe, n (%) | 30 (31.3) | 21 (40.0) | 9 (20.9) | |
Arteriolar hyalinosis, n (%) | 57 (56.4) | 38 (71.7) | 19 (42.2) | 0.016 |
Mild, n (%) | 42 (41.6) | 28 (52.8) | 14 (31.1) | |
Moderate, n (%) | 8 (7.9) | 5 (9.4) | 3 (6.7) | |
Severe, n (%) | 7 (6.9) | 5 (9.4) | 2 (4.7) | |
Tubular atrophy, n (%) | 80 (79.2) | 52 (92.9) | 38 (84.4) | 0.30 |
Mild, n (%) | 73 (72.3) | 42 (75.0) | 31 (68.9) | |
Moderate, n (%) | 13 (12.9) | 7 (12.5) | 6 (13.3) | |
Severe, n (%) | 4 (4.0) | 3 (5.4) | 1 (2.2) | |
Interstitial fibrosis, n (%) | 47 (46.5) | 28 (50.0) | 19 (42.2) | 0.30 |
Mild, n (%) | 31 (30.7) | 17 (30.4) | 14 (31.1) | |
Moderate, n (%) | 14 (13.9) | 9 (16.1) | 5 (11.1) | |
Severe, n (%) | 2 (2.0) | 2 (3.6) | 0 (0.0) | |
Pathological Diagnosis | ||||
Benign nephrosclerosis, n (%) | 8 (7.9) | 5 (8.9) | 3 (6.7) | 0.68 |
Mesangial proliferative GN, n (%) | 26 (25.7) | 12 (21.4) | 14 (31.1) | 0.27 |
IgA nephropathy, n (%) | 20 (19.8) | 8 (14.3) | 12 (26.7) | 0.12 |
IgA vasculitis, n (%) | 2 (2.0) | 1 (1.8) | 1 (2.2) | 0.88 |
Non-IgA mesangial proliferative GN, n (%) | 4 (4.0) | 3 (5.4) | 1 (2.2) | 0.42 |
Endocapillary proliferative GN, n (%) | 2 (2.0) | 1 (1.8) | 1 (2.2) | 0.88 |
Lupus nephritis, n (%) | 7 (6.9) | 3 (5.4) | 4 (8.7) | 0.40 |
ANCA-associated vasculitis, n (%) | 9 (8.9) | 6 (10.7) | 3 (6.7) | 0.48 |
Proteinuric glomerular diseases, n (%) | 37 (36.6) | 24 (42.9) | 13 (28.9) | 0.59 |
Minimal change disease, n (%) | 7 (6.9) | 2 (3.6) | 5 (11.1) | 0.14 |
Focal segmental glomerulosclerosis, n (%) | 2 (2.0) | 1 (1.8) | 1 (2.2) | 0.88 |
Membranous nephropathy, n (%) | 21 (20.8) | 16 (28.6) | 5 (11.1) | 0.03 |
Diabetic glomerulosclerosis, n (%) | 7 (6.9) | 5 (9.0) | 2 (4.4) | 0.38 |
Acute TIN/Acute tubular injury, n (%) | 8 (7.9) | 6 (10.8) | 2 (4.4) | 0.16 |
Minor glomerular abnormalities | 4 (4.0) | 3 (5.4) | 1 (2.2) | 0.42 |
Thrombotic microangiopathy | 2 (2.0) | 1 (1.8) | 1 (2.2) | 0.88 |
Thin basement membrane disease | 2 (2.0) | 1 (1.8) | 1 (2.2) | 0.88 |
Others, n (%) | 5 (5.0) | 0 (0.0) | 5 (11.1) | 0.01 |